SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'

Paves the Way to Launch its Second Innovative Drug Directly in the U.S. Announces agreement to in-license near-commercial candidate at a press conference Targets U.S. commercial launch as early as 2029… Upfront and milestone payments related to the Kv7 platform of up to $795M, plus tiered...